Design of a group-randomized Streptococcus pneumoniae vaccine trial.

A group-randomized, double-masked, phase III trial of a Streptococcus pneumoniae conjugate vaccine is being conducted in American Indian populations in the southwestern United States. Approximately 9000 infants will be enrolled in the primary efficacy cohort with vaccine allocation determined by community of residence. The trial is designed to continue until 48 cases of invasive pneumococcal disease due to vaccine serotypes have accumulated. Thirty-eight geographically and socially distinct areas were randomized within blocks formed by population size and geographic location. This design affords the opportunity to capture the effects of herd immunity (indirect effects) by estimating the impact of the vaccine intervention on nonimmunized infants. Group-randomized trials have challenging design and analysis features, many of which are discussed here in the context of the first such trial designed to lead to licensure of a drug or biologic in the United States.

[1]  D. Deegan.  Prevention of pneumococcal disease. , 1996, World of Irish nursing.

[2]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. , 2000, The Pediatric infectious disease journal.

[3]  M E Halloran,et al.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines. , 1997, American journal of epidemiology.

[4]  G. Filice,et al.  Pneumococcal bacteremia in Charleston County, South Carolina. , 1980, American journal of epidemiology.

[5]  S. Obaro.  Epidemiology of invasive pneumococcal disease. , 1995, The Journal of infectious diseases.

[6]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[7]  P. McCullagh,et al.  Generalized Linear Models , 1992 .

[8]  P. McCullagh,et al.  Generalized Linear Models, 2nd Edn. , 1990 .

[9]  R. Breiman,et al.  Pneumococcal bacteremia in Charleston County, South Carolina. A decade later. , 1990, Archives of internal medicine.

[10]  P E Fine,et al.  Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.

[11]  L. Brammer,et al.  Influenza surveillance--United States, 1992-93 and 1993-94. , 1997, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[12]  C. Schraer,et al.  Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. , 1989, JAMA.

[13]  J. Carlin,et al.  Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. The WHO Young Infants Study Group. , 1999, The Pediatric infectious disease journal.

[14]  D. Parks,et al.  The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention. , 1994, The Journal of infectious diseases.

[15]  P. Peduzzi,et al.  A review of the design of vaccine efficacy trials and a proposal for the design of the VA Cooperative Study of Active Immunotherapy of HIV Infection. , 1997, Controlled clinical trials.

[16]  M E Halloran,et al.  Direct and indirect effects in vaccine efficacy and effectiveness. , 1991, American journal of epidemiology.

[17]  A. van der Ende,et al.  Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. , 1997, The Journal of pediatrics.

[18]  J. Hedrick,et al.  High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. , 1995, The Pediatric Infectious Disease Journal.

[19]  L. Moulton,et al.  Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. , 2000, International journal of epidemiology.

[20]  G. Istre,et al.  Invasive disease due to Streptococcus pneumoniae in an area with a high rate of relative penicillin resistance. , 1987, The Journal of infectious diseases.

[21]  M. Santosham,et al.  High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. , 1992, Archives of internal medicine.

[22]  R. J. Hayes,et al.  Design and analysis issues in cluster-randomized trials of interventions against infectious diseases , 2000, Statistical methods in medical research.

[23]  R. Singleton,et al.  Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. , 1999, The Journal of infectious diseases.

[24]  Thomas C. Quinn,et al.  A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda , 1998, AIDS.

[25]  H. Campbell,et al.  The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. , 1992, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[26]  P. H. Leslie.  SOME FURTHER NOTES ON THE USE OF MATRICES IN POPULATION MATHEMATICS , 1948 .

[27]  Community Intervention Trial for Smoking Cessation (COMMIT): summary of design and intervention. COMMIT Research Group. , 1991, Journal of the National Cancer Institute.

[28]  B. Greenwood,et al.  The epidemiology of pneumococcal infection in children in the developing world. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[29]  A. J. Hall,et al.  Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation? , 1999, Vaccine.

[30]  John A. Nelder,et al.  Generalized linear models. 2nd ed. , 1993 .

[31]  R. Breiman,et al.  Prevention of pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997 .